Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Conditions
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma
- Follicular Variant Thyroid Gland Papillary Carcinoma
- Metastatic Thyroid Gland Follicular Carcinoma
- Metastatic Thyroid Gland Papillary Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Follicular Carcinoma
- Recurrent Thyroid Gland Papillary Carcinoma
- Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Stage III Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Hurthle Cell Carcinoma
- Unresectable Differentiated Thyroid Gland Carcinoma
- Unresectable Thyroid Gland Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- DRUG: Lenvatinib
- DRUG: Lenvatinib Mesylate
- BIOLOGICAL: Pembrolizumab
Sponsor
Academic and Community Cancer Research United
Collaborators